➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Dow
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

PARLODEL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Parlodel patents expire, and when can generic versions of Parlodel launch?

Parlodel is a drug marketed by Us Pharms Holdings I and is included in one NDA.

The generic ingredient in PARLODEL is bromocriptine mesylate. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

Drug patent expirations by year for PARLODEL
Drug Prices for PARLODEL

See drug prices for PARLODEL

Recent Clinical Trials for PARLODEL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San FranciscoPhase 1/Phase 2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)N/A
University of California, San FranciscoN/A

See all PARLODEL clinical trials

Pharmacology for PARLODEL

US Patents and Regulatory Information for PARLODEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 AB RX Yes No   Start Trial   Start Trial   Start Trial
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PARLODEL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982   Start Trial   Start Trial
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Dow
McKinsey
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.